Abstract:Introduction: The aromatase enzyme plays an important role in the progress of hormone-dependent breast cancer, especially in estrogen receptor-positive (ER+) breast cancers. In case of postmenopausal women, the aromatization of androstenedione to estrone in adipose tissue is the most important source of estrogen. Generally 60%-75% of pre- and post-menopausal women suffer from estrogen-dependent breast cancer, and thus suppressing estrogen has been recognized to be a successful therapy. Hence, to limit the stimulation of estrogen, aromatase inhibitors (AIs) are used in the second-line treatment of breast cancer. Methods: The present computational study employed an in silico approach in the identification of natural actives targeting the aromatase enzyme from a structurally diverse set of natural products. Molecular docking, QSAR studies and pharmacophore modeling were carried out using the VLife Molecular Design Suite (version 4.6). The stability of the compounds was confirmed by molecular dynamics. Results: From molecular docking and analysis of interactions with the amino acid residues of the binding cavity, it was found that the amino acid residues interacting with the non-steroidal inhibitors exhibited π-stacking interactions with PHE134, PHE 221, and TRP 224, while the steroidal drug exemestane lacked π-stacking interactions. QSAR studies were performed using the flavonoid compounds, in order to identify the structural functionalities needed to improve the anti-breast cancer activity. Molecular dynamics of the screened hits confirmed the stability of compounds with the target in the binding cavity. Moreover, pharmacophore modelling presented the pharmacophoric features of the selected scaffolds for aromatase inhibitory activity. Conclusion: The results presented 23 hit compounds that can be developed as anti-breast cancer modulating agents in the near future. Additionally, anthraquinone compounds with minor structural modification can also serve to be potential aromatase inhibitors. The in silico protocol utilised can be useful in the drug discovery process for development of new leads from structurally diverse set of natural products that are comparable to the drugs used clinically in breast cancer therapy.

[Progress in Study of the Structure, Catalytic Mechanism and Inhibitors of Aromatase].

Design, Synthesis and Activity of Flavonoids Aromatase Inhibitors

Recent Development in the Studies on Aromatase Inhibitors

Molecular Characterization of Aromatase

Screening for Aromatase Ligands in the Extract of Broussonetia Papyrifera Using High Performance Liquid Chromatography and ESI-mass Spectrometry

Syntheses and Qsar Studies of Benzylimidazole Derivatives and Benzylcarbazole As Potential Aromatase Inhibitors

Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs

Characterization Of Aromatase Binding Agents From The Dichloromethane Extract Of Corydalis Yanhusuo Using Ultrafiltration And Liquid Chromatography Tandem Mass Spectrometry

Synthesis and Biological Evaluation of Aromatase Inhibitors

Potent Aromatase Inhibitors and Molecular Mechanism of Inhibitory Action

Aromatase inhibition and inactivation

Insight into the Enzyme-Inhibitor Interactions of the First Experimentally Determined Human Aromatase

Screening for Ligands of Human Aromatase from Mulberry (mori Alba L.) Leaf by Using High-Performance Liquid Chromatography/tandem Mass Spectrometry

Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer

Unlocking the potential of aromatase inhibitors: recent advances in drug design, synthesis, docking activity, and in vitro bioactivity evaluations

Polyphenolic natural products and natural product–inspired steroidal mimics as aromatase inhibitors

Origin of aromatase inhibitory activity via proteochemometric modeling

Current perspectives on aromatase inhibitors in breast cancer

Progress of research on the screening models of aromatase inhibitors

Aromatase inhibitors: new endocrine treatment of breast cancer

Two Natural Products, Trans-Phytol and (22E)-Ergosta-6,9,22-triene-3β,5α,8α-triol, Inhibit the Biosynthesis of Estrogen in Human Ovarian Granulosa Cells by Aromatase (CYP19)